Laura Brodzinsky

Dr. Steffner specializes in the evaluation, diagnosis, and treatment of bone and soft tissue tumors in pediatric and adult patients. This includes primary bone and soft tissue sarcomas, locally active conditions such as giant cell tumor, aneurysmal bone cyst, and chondroblastoma, as well as impending and pathologic fractures from metastatic carcinoma, multiple myeloma, and lymphoma. He works closely with the multidisciplinary sarcoma group at the Stanford Cancer Center to provide coordinated, highly specialized treatment strategies.

Dr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.

Dr. Rezvani is an Associate Professor of Medicine in the Division of Blood & Marrow Transplantation and Cellular Therapy. He serves as the medical director of the inpatient BMT/cell therapy units at Stanford University and as Associate Clinical Chief of the Division. As a clinician, he cares for people undergoing allogeneic and autologous hematopoietic cell transplantation and other forms of cellular therapy. His research interests include optimizing the use of alternative donors for people who lack traditional fully-matched donors; the prevention and treatment of graft-vs.-host disease; the role of the microbiome in hematopoietic cell transplantation; and quality-of-care and systems improvement.